

Empower Clinics Inc.

08:20 27 Apr 2020

Empower Clinics joins fight against coronavirus pandemic with four-phase US rollout of antibody testing

Empower Clinics Inc (CSE:CBDT) (OTCMKTS:EPWCF) is helping in the fight against the global pandemic and revealed it has started coronavirus (COVID-19) antibody testing at its Sun Valley Health clinics in Phoenix, Arizona, USA.

The health and wellness group has established a four-phase national testing program using RAPID COVID-19 test kits, it said in a statement on Monday.

Antibody testing is an essential part of the battle against the disease because it can help to establish who, and how many people, have been infected.

READ: Empower Clinics launches psilocybin research and psychedelic treatment subsidiary

Phase One of Empower's program sees blood draw testing at its clinics in Arizona, using clinic phlebotomists. Samples are sent to Empower's laboratory test partner for analysis, with results expected within 48 hours.

Phase Two offers a Rapid COVID-19 antibody test with results in 1-15 minutes. The service will be offered in-clinics using a drive-up service, conducted by the firm's clinic staff, as well as a door-step service, using certified mobile technicians. Empower expects phase two services will begin in May this year.

Phase Three are so-called Business Employee Testing (BET) programs, also expected to kick off in May. These offer Rapid COVID-19 testing to businesses on a one-time basis, repeat basis and/or subscription basis, to assist businesses to get back to work safely.

Phase Four is a US nationwide roll-out, offering all phases of the company services, that can be accessed online at Empower websites and call centers, to purchase Rapid COVID-19 test kits. The company anticipates Phase Four services to start in the third quarter of this year.

"Our team are ready to meet the crisis head-on, and we have ensured that the test processes and the test kits we use, are approved in the United States under the Emergency Use Authorization (EUA), as defined by the U.S. Food and Drug Administration (FDA)," Steven McAuley, the chairman and CEO at Empower said in the statement.

Empower has secured test kit supply agreements with two suppliers - NanoID Technologies Pty Ltd and Emunah Trust, LLC.

Contact the author at giles@proactiveinvestors.com

Price: 0.07

Market Cap: \$13.74 m

1 Year Share Price Graph



Share Information

Code: CBDT

Listing: CSE

52 week High Low
0.13 0.025

Sector: Cannabis

Website: www.empowerclinics.com

Company Synopsis:

Empower Clinics Inc. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Empower Clinics Inc. named herein, including the promotion by the Company of Empower Clinics Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).